发明授权
US09347051B2 Coagulation factor X polypeptides with modified activation properties
有权
具有改变的活化特性的凝血因子X多肽
- 专利标题： Coagulation factor X polypeptides with modified activation properties
- 专利标题（中）： 具有改变的活化特性的凝血因子X多肽
-
申请号： US12224182申请日： 2007-02-19
-
公开(公告)号： US09347051B2公开(公告)日： 2016-05-24
- 发明人: Stefan Schulte , Hans-Peter Hauser , Uwe Kalina , Thomas Weimer
- 申请人： Stefan Schulte , Hans-Peter Hauser , Uwe Kalina , Thomas Weimer
- 申请人地址： DE Marburg
- 专利权人： CSL BEHRING GMBH
- 当前专利权人： CSL BEHRING GMBH
- 当前专利权人地址： DE Marburg
- 代理机构： Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
- 优先权： EP06003475 20060221
- 国际申请： PCT/EP2007/001417 WO 20070219
- 国际公布： WO2007/096116 WO 20070830
- 主分类号： C07K19/00
- IPC分类号： C07K19/00 ; C07K4/12 ; C07K14/745 ; C12N9/64 ; A61K38/01 ; A61K38/36
摘要：
The present invention relates to modified cDNA sequences coding for factor X polypeptides, in particular human factor X and its derivatives which can bypass the need for either factor VIIIa/factor IXa or factor VIIa/tissue factor for activation. The invention relates further to recombinant expression vectors containing such modified cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having altered activation properties, and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
公开/授权文献
信息查询
